Tydemy Kit
Product Images NDC 68180-904

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Tydemy (NDC 68180-904). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (8a0382f9 25e1 4fd2 8958 152520ad8ce4 01)

A forest plot chart displaying hazard ratios, rate ratios, and odds ratios from various studies including prospective cohort, retrospective cohort, case-control, and non-fatal idiopathic cases only. The x-axis represents the ratio scale from 0.1 to 10, with plotted points and confidence intervals showing the study results.*

FDA Label Image

Image (8a0382f9 25e1 4fd2 8958 152520ad8ce4 02)

A horizontal bar chart depicting the duration of pregnancy-related states and their respective ranges in weeks based on a sample of 10,000 women years (AWY). The chart includes four categories: Non-Pregnant Non-COC user (range 1 to 5 weeks), COC-User (range 3 to 8 weeks), Pregnancy (range 5 to 20 weeks), and Postpartum (12 weeks only, range 48 to 65 weeks).*

FDA Label Image

Image (8a0382f9 25e1 4fd2 8958 152520ad8ce4 03)

A forest plot comparing effect estimates from multiple studies, showing odds ratios (OR), relative risks (RR), and hazard ratios (HR) with their confidence intervals. The studies include investigations on contraceptive use with labels such as "Ever COC vs. Never COC Use" and "Current COC use vs. Never-Use," with horizontal lines representing confidence intervals around each study's point estimate on an Effect Estimate scale ranging roughly from -1.5 to 2.0.*

FDA Label Image

Image (8a0382f9 25e1 4fd2 8958 152520ad8ce4 04)

Chemical structure diagrams of three active ingredients: Drospirenone, Ethinyl Estradiol, and Levomefolate Calcium. Each structure is labeled with the compound name and shows the molecular arrangement of atoms and bonds for these substances found in Tydemy by Lupin Pharmaceuticals.*

FDA Label Image

Image (8a0382f9 25e1 4fd2 8958 152520ad8ce4 05)

A line graph comparing plasma folate levels over 24 weeks between two groups: YAZ plus levomefolate calcium and YAZ alone. The x-axis shows time in weeks, and the y-axis shows plasma folate concentration in nmol/L. Data include mean values with standard deviation error bars for each time point, indicating differences in folate levels between the two treatments over time.*

FDA Label Image

Image (8a0382f9 25e1 4fd2 8958 152520ad8ce4 06)

A line graph showing RBC folates levels (nmol/L) over 24 weeks, comparing YAZ with levomefolate calcium (square markers) and YAZ alone (circle markers). The graph includes arithmetic means with standard deviations for two populations (N=122 and N=44) across multiple time points from pre-treatment to 24 weeks.*

FDA Label Image

Image (8a0382f9 25e1 4fd2 8958 152520ad8ce4 07)

This line chart shows plasma folate levels (nmol/L) over time (weeks) with arithmetic mean values and standard deviations. It compares women receiving Yasmin plus levomefolate calcium during the treatment phase and Yasmin only during the elimination phase, illustrating changes from pre-treatment through 44 weeks.*

FDA Label Image

Image (8a0382f9 25e1 4fd2 8958 152520ad8ce4 08)

A line chart showing RBC folates (nmol/L) levels over time (weeks) for patients taking Yasmin with levomefolate calcium. The chart spans from pre-treatment through treatment and elimination phases, presenting mean values with standard deviation error bars based on biweekly measurements.*

FDA Label Image

Image (8a0382f9 25e1 4fd2 8958 152520ad8ce4 09)

An illustration diagram showing a vertical scale representing pregnancy frequency ranging from fewer than 1 pregnancy to 85 or more pregnancies per 100 women in one year. The diagram categorizes birth control methods by their effectiveness, listing implants, injections, intrauterine devices, and sterilization as most effective; birth control pills, skin patch, and vaginal ring with hormones as moderately effective; condoms and diaphragm as less effective; behavioral methods like avoiding sex during fertile days, spermicides, and withdrawal as even less effective; and no birth control at the least effective.*

FDA Label Image

Image (8a0382f9 25e1 4fd2 8958 152520ad8ce4 10)

An instructional diagram showing a 28-day weekly pill pack for Tydemy by Lupin Pharmaceuticals. It includes labeled rows for Week 2, Week 3, and Week 4 and days of the week from Sunday to Saturday. Instructions indicate placement of a day label strip if the period begins on a day other than Sunday. There is a reminder for monthly self breast exam.*

FDA Label Image

Image (8a0382f9 25e1 4fd2 8958 152520ad8ce4 11)

A horizontal bar chart depicting the number of women with blood clots per 10,000 women years (WY) across four groups: Non-Pregnant Non-COC users (range 1 to 5), COC users (range 3 to 9), Pregnant women (range 5 to 20), and Postpartum women (12 weeks only) with the highest range (40 to 65).*

FDA Label Image

Lable (8a0382f9 25e1 4fd2 8958 152520ad8ce4 12)

Tydemy tablet blister packaging label including dosage and storage instructions. The product contains drospirenone, ethinyl estradiol, and levomefolate calcium tablets at strengths of 3 mg, 0.03 mg, and 0.451 mg respectively. The label indicates storage temperatures, manufacturer Lupin Limited in India, and distributor Lupin Pharmaceuticals, Inc. in the US. The blister is arranged in a 28-day calendar format for daily dosing with a reminder for monthly self breast exam.*

FDA Label Image

Lable (8a0382f9 25e1 4fd2 8958 152520ad8ce4 13)

Packaging label for Tydemy, a tablet product by Lupin Pharmaceuticals, Inc. The label states the active ingredients as drospirenone, ethinyl estradiol, and levomefolate calcium with dosages of 3 mg/0.03 mg/0.451 mg, respectively. It contains 1 blister with 28 tablets. The label includes instructions that the product is prescription only and highlights its use as an oral contraceptive.*

FDA Label Image

Lable (8a0382f9 25e1 4fd2 8958 152520ad8ce4 14)

Packaging label for Tydemy tablets by Lupin Pharmaceuticals, Inc. The label lists the active ingredients as drospirenone, ethinyl estradiol, and levomefolate calcium with strengths of 3 mg/0.03 mg/0.451 mg respectively, along with levomefolate calcium tablets at 0.451 mg. The package contains 3 blisters of 28 tablets each. The label includes an NDC 68180-904-73, a barcode, and distributor and manufacturer information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.